Pneumocystis jirovecii pneumonia: Difference between revisions

(Text replacement - "0 mg" to "0mg")
(Text replacement - "==Treatment==" to "==Management==")
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
''Note: this page is about the infection. For the drug PCP, see [[Phencyclidine]]''
==Background==
==Background==
*Abreviations: PCP (formerly known as Pneumocystis carinii pneumonia) or PJP
*Abreviations: PCP (formerly known as Pneumocystis carinii pneumonia) or PJP
Line 22: Line 23:
{{HIV associated conditions}}
{{HIV associated conditions}}


==Diagnosis==
==Evaluation==
*CBC
*CBC
*Chemistry
*Chemistry
Line 28: Line 29:
*ABG
*ABG
*CD4 count
*CD4 count
*CXR - bat wing appearance (bilat interstitial infiltrates)
*[[CXR]] - bat wing appearance (bilat interstitial infiltrates)
*A-a gradient
*A-a gradient
**P(A-a)O2 = 150 – (PaCO2/0.8) – PaO2 at sea level on RA (normal is <10 in young, healthy patients)
**P(A-a)O2 = 150 – (PaCO2/0.8) – PaO2 at sea level on RA (normal is <10 in young, healthy patients)
Line 34: Line 35:


*Imaging
*Imaging
**CXR
**[[CXR]]
***Normal in 25% of cases
***Normal in 25% of cases
***Diffuse, interstitial infiltrates
***Diffuse, interstitial infiltrates
Line 41: Line 42:
***May see ground glass infiltrative pattern
***May see ground glass infiltrative pattern


==Treatment==
==Management==
===[[Antibiotics]]===
===[[Antibiotics]]===
*Require [[HCAP]] or [[CAP]] (ceftriaxone and azithromycin) coverage as well<ref>Rothmans RE, Marco CA, Yang S. Human immunodeficiency virus infection and acquired immunodeficiency syndrome, in Tintinalli JE, Stapczynski JS, Ma OJ, et al (eds): Tintinalli’s Emergency Medicine, ed 7. New York, The McGraw-Hill Companies Inc., 2011.</ref>
*Require [[HCAP]] or [[CAP]] (ceftriaxone and azithromycin) coverage as well<ref>Rothmans RE, Marco CA, Yang S. Human immunodeficiency virus infection and acquired immunodeficiency syndrome, in Tintinalli JE, Stapczynski JS, Ma OJ, et al (eds): Tintinalli’s Emergency Medicine, ed 7. New York, The McGraw-Hill Companies Inc., 2011.</ref>
Line 47: Line 48:


===Corticosteroids===
===Corticosteroids===
*Only in patients with HIV with severe respiratory parameters:
*Only in patients with [[HIV]] with severe respiratory parameters:
**Room air PaO2 < 70 mmHg
**Room air PaO2 < 70 mmHg
**OR A-a gradient > 35 mmHg
**'''OR''' A-a gradient > 35 mmHg
*Treatment schedule for moderate to severe PCP<ref>Wilken A, Feinberg J. Pneumocystis carinii Pneumonia: A Clinical Review. Am Fam Physician. 1999 Oct 15;60(6):1699-1708. http://www.aafp.org/afp/1999/1015/p1699.html.</ref>
*Treatment schedule for moderate to severe PCP<ref>Wilken A, Feinberg J. Pneumocystis carinii Pneumonia: A Clinical Review. Am Fam Physician. 1999 Oct 15;60(6):1699-1708. http://www.aafp.org/afp/1999/1015/p1699.html.</ref>
**Day 1-5: 40mg prednisone BID
**Day 1-5: 40mg [[prednisone]] BID
**Day 6-10: 40mg prednisone once daily
**Day 6-10: 40mg [[prednisone]] once daily
**Day 11-21: 20mg prednisone once daily
**Day 11-21: 20mg [[prednisone]] once daily
**Patients too ill to take PO may take equivalent IV methylprednisolone
**Patients too ill to take PO may take equivalent IV methylprednisolone



Revision as of 19:21, 11 December 2017

Note: this page is about the infection. For the drug PCP, see Phencyclidine

Background

  • Abreviations: PCP (formerly known as Pneumocystis carinii pneumonia) or PJP
  • Pneumocystis (carinii) jiroveci
  • Most common opportunistic infection in AIDS patients
  • Most common identifiable cause of death

Risk factors

  • CD4 < 200
  • Immunosuppressive medications
  • Cancer
  • Primary immunodeficiencies
  • Severe malnutrition

Clinical Features

Differential Diagnosis

Acute dyspnea

Emergent

Non-Emergent

HIV associated conditions

Evaluation

  • CBC
  • Chemistry
  • LDH elevation - sensitive but not specific
  • ABG
  • CD4 count
  • CXR - bat wing appearance (bilat interstitial infiltrates)
  • A-a gradient
    • P(A-a)O2 = 150 – (PaCO2/0.8) – PaO2 at sea level on RA (normal is <10 in young, healthy patients)
    • Increased in PCP pneumonia secondary to decreased diffusion thru thick aveoli
  • Imaging
    • CXR
      • Normal in 25% of cases
      • Diffuse, interstitial infiltrates
    • CT Chest
      • Sn 100%, Sp 89%
      • May see ground glass infiltrative pattern

Management

Antibiotics

  • Require HCAP or CAP (ceftriaxone and azithromycin) coverage as well[2]

Mild Disease

  • TMP/SMX 2 DS tablets PO q8hrs daily OR
    • High incidence of allergy in HIV
  • Dapsone 100mg PO once daily + TMP 5mg/kg PO q8hrs OR
    • caution: dapsone can cause methemoglobinemia
  • Atavaquone 750mg PO q12hrs OR
  • Primaquine 30mg PO q24hrs + Clindamycin 450mg PO q8hrs

Severe Disease

  • TMP/SMX 5mg/kg IV q8hrs daily x 21 days OR
  • Pentamidine 4mg/kg IV daily infused over 60 minutes OR
    • Watch for side effects of hypoglycemia and hypotension
  • Primaquine 30mg PO once daily + Clindamycin 900mg IV q8hrs daily

Prophylaxis

  • TMP/SMX 1 double strength tablet daily, but one single strength tablet daily or one double-strength three times weekly is acceptable.[3]

Corticosteroids

  • Only in patients with HIV with severe respiratory parameters:
    • Room air PaO2 < 70 mmHg
    • OR A-a gradient > 35 mmHg
  • Treatment schedule for moderate to severe PCP[4]
    • Day 1-5: 40mg prednisone BID
    • Day 6-10: 40mg prednisone once daily
    • Day 11-21: 20mg prednisone once daily
    • Patients too ill to take PO may take equivalent IV methylprednisolone

Disposition

  • Symptoms usually worsen 2-3d after start of treatment
  • Patients with disease severe enough to warrant IV therapy or steroids should be admitted

References

  1. Gutteridge, David L MD, MPH, Egan, Daniel J. MD. The HIV-Infected Adult Patient in The Emergency Department: The Changing Landscape of the Disease. Emergency Medicine Practice: An Evidence-Based Approach to Emergency Medicine. Vol 18, Num 2. Feb 2016.
  2. Rothmans RE, Marco CA, Yang S. Human immunodeficiency virus infection and acquired immunodeficiency syndrome, in Tintinalli JE, Stapczynski JS, Ma OJ, et al (eds): Tintinalli’s Emergency Medicine, ed 7. New York, The McGraw-Hill Companies Inc., 2011.
  3. CDC Guidelines for Prophylaxis Against Pneumocystis carinii Pneumonia for Children Infected with Human Immunodeficiency Virus http://www.cdc.gov/mmwr/preview/mmwrhtml/00001957.htm
  4. Wilken A, Feinberg J. Pneumocystis carinii Pneumonia: A Clinical Review. Am Fam Physician. 1999 Oct 15;60(6):1699-1708. http://www.aafp.org/afp/1999/1015/p1699.html.